文献速递中医内科中药与中成药合理使用

麝香心通宁抗冠心病药理机制的网络药理学与实验验证研究

Investigating the Pharmacological Mechanisms of SheXiang XinTongNing Against Coronary Heart Disease Based on Network Pharmacology and Experimental Evaluation.
PubMed 文献 · Front Pharmacol · 2021-07-14

本研究采用网络药理学与实验验证相结合的方法,探讨由六味中药组成的已上市中成药麝香心通宁(XTN)抗冠心病(CHD)的药理机制。研究先通过GO和KEGG富集分析及网络构建预测潜在活性成分、候选靶点与机制,再经体外MTT、流式细胞术、RT-qPCR及体内Tunel染色和免疫组化验证。结果显示Bcl-2、IGF1、CASP3为关键候选靶点,与PI3K-Akt和MAPK信号通路显著相关,XTN可降低H9c2细胞凋亡率及Bax/Bcl-2比值,并减轻心肌缺血所致氧化损伤、抑制细胞凋亡,提示其通过调控凋亡通路保护心脏。

要点

  • XTN可能通过调控PI3K-Akt与MAPK通路及凋亡相关靶点Bcl-2、IGF1、CASP3发挥抗CHD作用。
  • 体外实验显示XTN可降低H9c2细胞凋亡率及Bax/Bcl-2比值。
  • 体内组织学结果提示XTN减轻心肌缺血氧化损伤并抑制细胞凋亡。

核心结论

  • XTN通过调控凋亡通路保护心脏免受氧化应激,为其抗CHD作用提供了机制依据。

研究设计与样本

  • 研究采用网络药理学预测结合体外与体内实验验证的方法。
  • 体外实验包括MTT法、流式细胞术和实时定量PCR分析。
  • 体内实验包括Tunel染色和免疫组化染色。

主要发现

  • Bcl-2、IGF1、CASP3为与多条通路显著相关的关键候选靶点。
  • 关键靶点显著关联PI3K-Akt信号通路和MAPK信号通路。
  • XTN处理显著降低H9c2细胞凋亡率及Bax/Bcl-2比值。
  • 组织学结果证实XTN减轻心肌缺血所致氧化损伤并抑制细胞凋亡。

临床怎么用

  • 机制层面支持XTN用于CHD时可能通过调控凋亡与氧化应激通路获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SheXiang XinTongNing (XTN), which is composed of six traditional Chinese herbs, is a commercially available Chinese patent medicine that has been widely used as the treatment of coronary heart disease (CHD). Its mechanisms against coronary heart disease, however, remain largely unknown. This study aimed to investigate the pharmacological mechanisms of XTN against CHD via network pharmacology and experimental evaluation. In this study, GO enrichment and KEGG pathway enrichment were firstly performed for acquiring the potentially active constituents of XTN, the candidate targets related to coronary heart disease, the drug-components-targets network as well as the protein-protein interaction network and further predicting the mechanisms of XTN against coronary heart disease. Subsequently, a series of in vitro experiments, specifically MTT assay, flow cytometry and Real-time quantitative polymerase chain reaction analysis, and a succession of in vivo experiments, including Tunel staining and immunohistochemical staining were conducted for further verification. Results showed that Bcl-2, IGF1, CASP3 were the key candidate targets which significantly associated with multiple pathways, namely PI3K-Akt signaling pathway and MAPK signaling pathway. It indicated that the potential mechanism of XTN against CHD may be predominantly associated with cell apoptosis. The in vitro experimental results showed that XTN treatment remarkably decreased the apoptotic rate and Bax/Bcl-2 ratio of H9c2 cells. Histological results confirmed that XTN not only effectively alleviated oxidative damage caused by myocardial ischemia but inhibited cell apoptosis. Given the above, through the combined utilization of virtual screening and experimental verification, the findings suggest that XTN makes a significant contribution in protecting the heart from oxidative stress via regulating apoptosis pathways, which lays the foundations and offers an innovative idea for future research.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Jia LY, Cao GY, Li J, et al. Investigating the Pharmacological Mechanisms of SheXiang XinTongNing Against Coronary Heart Disease Based on Network Pharmacology and Experimental Evaluation. Front Pharmacol. 2021. PMID: 34335263. doi:10.3389/fphar.2021.698981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。